Results 81 to 90 of about 19,789 (243)

Complete seizure freedom following minimally invasive laser callosotomy in a patient with lissencephaly type 1: Challenging the traditional paradigm

Epileptic Disorders, EarlyView.
Agilda Dema, Archie Baskaran, Joshua Chang, Douglas Nordli III, Peter Warnke   +4 more
wiley   +1 more source

Corticocortical evoked potential amplitude is altered by cortical stimulation in epilepsy

Epilepsia, EarlyView.
Abstract Objective Neurostimulation is an established therapy for drug‐resistant epilepsy, but optimizing stimulation parameters remains a major challenge. Corticocortical evoked potential (CCEP) amplitude may serve as an immediate biomarker of neurostimulation effects, enabling rapid parameter optimization.
Bethany J. Stieve, Aaron F. Struck, Dillon Scott, Richard Chappell, Andrew T. Knox   +4 more
wiley   +1 more source

Low diagnostic yield of presurgical genetic testing in adult patients with epilepsy

Epilepsia, EarlyView.
Abstract Objective To determine the diagnostic yield of genetic testing in patients undergoing presurgical evaluation for epilepsy. Methods We conducted a cohort study including 115 adult patients who underwent presurgical evaluation in the Calgary Epilepsy Program between 2019 and 2023 and who had undergone research exome sequencing.
Clara Jünemann, Amanda Stuart, Navprabhjot Kaur, Samuel Wiebe, Nathalie Jette, Shaily Singh, Felippe Borlot, Susanne Knake, The Calgary Comprehensive Epilepsy Program Collaborators, Paolo Federico, Colin Josephson, William Murphy, Andrea Salmon, Guillermo Delgado Garcia, Walter Hader, Ping Yee Billie Au, Karl Martin Klein   +16 more
wiley   +1 more source

Sustained seizure freedom with fenfluramine for refractory epilepsy due to 7q32‐q34 deletion syndrome

Epileptic Disorders, EarlyView.
Divya Veerapaneni, Abdulrahman Bukhari, Irfan S. Sheikh   +2 more
wiley   +1 more source

Seizure relapse in new onset epilepsy: It is not always drug resistance

Epilepsia, EarlyView.
Abstract Objective Seizure recurrence in new onset epilepsy (NOE) can result from various factors. Although drug ineffectiveness is frequently investigated, other causes—such as nonadherence, inadequate treatment, nonepileptic events (e.g., functional/dissociative), or acute symptomatic seizures—also impact patient outcomes.
Cecilia Catania, Eric Menetre, Aikaterini Fitsiori, Felix Tobias Kurz, Gabriela Moreno Legast, Serge Vulliemoz, Mathieu Genoud, Pierre Mégevand, Roland Wiest, Fabienne Picard, Sandor Beniczky, Margitta Seeck   +11 more
wiley   +1 more source

Functional/dissociative seizures as a manifestation of forced normalization in eyelid myoclonia with absence epilepsy

Epileptic Disorders, EarlyView.
Fernando Vasquez‐Lopez, Jimena Gonzalez‐Salido, Salvador Martínez‐Medina, Irving Fuentes‐Calvo, Diego A. Barrios‐González, Betsy C. Vázquez‐Cruz, Juan Carlos Vera‐López, Jimena Colado‐Martinez, Orelli Ruiz‐Rodríguez, Pilar Robles‐Lomelin, Maximiliano Salgado Deza, Diego A. Hernandez, Álvaro José Moreno Avellán, Mario A. Sebastián Díaz, Daniel Crail‐Meléndez, Ángel Ruiz‐Chow, Iris E. Martínez‐Juárez   +16 more
wiley   +1 more source

Long‐term prognosis of pharmacotherapy in newly diagnosed focal epilepsy patients and the predictive value of baseline seizure timing: A prospective cohort study

Epilepsia, EarlyView.
Abstract Objective Epilepsy is a highly heterogeneous neurological disorder with significant prognostic variability. Accurate long‐term outcome prediction remains a clinical challenge. We investigated pharmacotherapeutic prognosis and key predictors, particularly baseline seizure timing, to guide individualized treatment.
Lei Sun, Shouye Sun, Xinyue Zhang, Weihong Lin   +3 more
wiley   +1 more source

Add‐on treatment with vinpocetine reduces seizure frequency and improves comorbidities in patients with loss‐of‐function γ‐aminobutyric acid type A receptor variants

Epilepsia, EarlyView.
Abstract Objective The semisynthetic compound vinpocetine has gained attention as a potential precision medicine for developmental and epileptic encephalopathies caused by loss‐of‐function (LoF) variants in γ‐aminobutyric acid type A (GABAA) receptor genes. As a positive allosteric modulator of GABAA receptors, case reports suggest that vinpocetine can
Cathrine E. Gjerulfsen, Vivian W. Y. Liao, Tomasz S. Mieszczanek, Anne V. Jakobsen, Elena Gardella, Kern Olofsson, Marina Nikanorova, Allan Bayat, Sebastian Ortiz, Sarah Weckhuysen, Cecilie Johannessen Landmark, Orrin Devinsky, Mary Chebib, Philip K. Ahring, Guido Rubboli, Rikke S. Møller   +15 more
wiley   +1 more source

Compensatory rearrangement of parvalbumin interneuron voltage‐gated sodium channel subunits in a mouse model of Dravet syndrome

Epilepsia, EarlyView.
Abstract Heterozygous loss‐of‐function variants in the gene SCN1A, which encodes the voltage‐gated sodium channel (VGSC) pore‐forming (α) subunit NaV1.1, lead to a spectrum of neurological disease, including Dravet syndrome. NaV1.1 is prominently expressed at the proximal portion of the axon initial segment (AIS) of fast‐spiking γ‐aminobutyric ...
Ania K. Dabrowski, Ala Somarowthu, Sophie R. Liebergall, Damaris N. Lorenzo, Ethan M. Goldberg   +4 more
wiley   +1 more source

Gamma suppression correlates with thalamic stimulation therapeutic response in intractable epilepsy

Epilepsia, EarlyView.
Abstract Objective In patients with drug‐resistant epilepsy who undergo anterior nucleus of the thalamus (ANT) deep brain stimulation (DBS), efficacy is assessed months after therapy initiation and clinicians have no guidance when choosing stimulation parameters due to the lack of real‐time biomarkers.
Zachary T. Sanger, Xinbing Zhang, Thomas Lisko, Hafsa Farooqi, Steffen Ventz, Sandipan Pati, Thomas R. Henry, David P. Darrow, Michael C. Park, Theoden I. Netoff, Robert A. McGovern   +10 more
wiley   +1 more source